Weekly shot could replace daily needles for kids with growth hormone deficiency
NCT ID NCT02781727
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether a once-weekly injection of TransCon hGH works as well as daily growth hormone injections in prepubertal children with growth hormone deficiency. About 150 children who have not received growth hormone treatment before will receive either the weekly shot or daily injections for 52 weeks. The main goal is to compare how much the children grow over the year. If successful, this could mean fewer injections for children and their families.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TransCon hGH (lonapegsomatropin)
- What this could lead to
- If successful, children with growth hormone deficiency could switch from daily injections to a single weekly shot, reducing treatment burden.
- What could go wrong
- This is a phase 3 trial, but results may not confirm non-inferiority or better safety versus daily hGH. Long-term effects beyond 52 weeks are not yet known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOCRINE SYSTEM DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ascendis Pharma Investigational Site
Birmingham, Alabama, 35233, United States
-
Ascendis Pharma Investigational Site
Little Rock, Arkansas, 72202, United States
-
Ascendis Pharma Investigational Site
Los Angeles, California, 90048, United States
-
Ascendis Pharma Investigational Site
Orange, California, 92868, United States
-
Ascendis Pharma Investigational Site
Centennial, Colorado, 80112, United States
-
Ascendis Pharma Investigational Site
Jacksonville, Florida, 32207, United States
-
Ascendis Pharma Investigational Site
Orlando, Florida, 32806, United States
-
Ascendis Pharma Investigational Site
Saint Paul, Minnesota, 55102, United States
-
Ascendis Pharma Investigational Site
Jackson, Mississippi, 39216, United States
-
Ascendis Pharma Investigational Site
Lebanon, New Hampshire, 03756, United States
-
Ascendis Pharma Investigational Site
Mineola, New York, 11501, United States
-
Ascendis Pharma Investigational Site
Oklahoma City, Oklahoma, 73104, United States
-
Ascendis Pharma Investigational Site
Portland, Oregon, 97239, United States
-
Ascendis Pharma Investigational Site
Dallas, Texas, 75235, United States
-
Ascendis Pharma Investigational Site
Fort Worth, Texas, 76104, United States
-
Ascendis Pharma Investigational Site
Tacoma, Washington, 98405, United States
-
Ascendis Pharma Investigational Site
Yerevan, 0075, Armenia
-
Ascendis Pharma Investigational Site
Clayton, 3168, Australia
-
Ascendis Pharma Investigational Site
Minsk, 220020, Belarus
-
Ascendis Pharma Investigational Site
Varna, 9010, Bulgaria
-
Ascendis Pharma Investigational Site
Tbilisi, 0144, Georgia
-
Ascendis Pharma Investigational Site
Tbilisi, 0159, Georgia
-
Ascendis Pharma Investigational Site
Tbilisi, 0162, Georgia
-
Ascendis Pharma Investigational Site
Athens, 11527, Greece
-
Ascendis Pharma Investigational Site
Milan, 20157, Italy
-
Ascendis Pharma Investigational Site
Roma, 00165, Italy
-
Ascendis Pharma Investigational Site
Grafton, 1023, New Zealand
-
Ascendis Pharma Investigational Site
Warsaw, 02-691, Poland
-
Ascendis Pharma Investigational Site
Iași, 700111, Romania
-
Ascendis Pharma Investigational Site
Izhevsk, 426009, Russia
-
Ascendis Pharma Investigational Site
Kazan', 420138, Russia
-
Ascendis Pharma Investigational Site
Krasnoyarsk, 620022, Russia
-
Ascendis Pharma Investigational Site
Moscow, 125373, Russia
-
Ascendis Pharma Investigational Site
Moscow, 127994, Russia
-
Ascendis Pharma Investigational Site
Nizhny Novgorod, 603136, Russia
-
Ascendis Pharma Investigational Site
Novosibirsk, 630048, Russia
-
Ascendis Pharma Investigational Site
Omsk, 644001, Russia
-
Ascendis Pharma Investigational Site
Saint Petersburg, 191144, Russia
-
Ascendis Pharma Investigational Site
Saint Petersburg, 194100, Russia
-
Ascendis Pharma Investigational Site
Samara, 443079, Russia
-
Ascendis Pharma Investigational Site
Saratov, 410054, Russia
-
Ascendis Pharma Investigational Site
Tomsk, 634050, Russia
-
Ascendis Pharma Investigational Site
Ufa, 450008, Russia
-
Ascendis Pharma Investigational Site
Vologda, 160022, Russia
-
Ascendis Pharma Investigational Site
Voronezh, 394024, Russia
-
Ascendis Pharma Investigational Site
Izmir, 35100, Turkey (Türkiye)
-
Ascendis Pharma Investigational Site
Melikgazi, 38039, Turkey (Türkiye)
-
Ascendis Pharma Investigational Site
Trabzon, 61080, Turkey (Türkiye)
-
Ascendis Pharma Investigational Site
Kharkiv, 61093, Ukraine
-
Ascendis Pharma Investigational Site
Kyiv, 01021, Ukraine
-
Ascendis Pharma Investigational Site
Kyiv, 04114, Ukraine
-
Ascendis Pharma Investigational Site
Odesa, 65031, Ukraine
-
Ascendis Pharma Investigatonal Site
Gdansk, 80-952, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Childhood brain tumor survivors face hidden hormone risks years later
- Could a metabolic modulator help people with type 1 diabetes use insulin better?
- Weekly shot could replace daily needles for kids with growth hormone deficiency
- Weekly shot could replace daily growth hormone injections for children
- Weekly shot could replace daily hormone injections for growth hormone deficiency
- Could a targeted drug delay prostate cancer progression?